| Primary |
| Drug Use For Unknown Indication |
17.8% |
| Product Used For Unknown Indication |
16.8% |
| Prophylaxis |
12.0% |
| Fungal Infection |
9.0% |
| Aspergillosis |
8.3% |
| Antifungal Prophylaxis |
7.5% |
| Bronchopulmonary Aspergillosis |
6.0% |
| Zygomycosis |
4.3% |
| Acute Myeloid Leukaemia |
3.2% |
| Chemotherapy |
2.5% |
| Fusarium Infection |
1.7% |
| Graft Versus Host Disease |
1.7% |
| Pyrexia |
1.7% |
| Antifungal Treatment |
1.3% |
| Chronic Granulomatous Disease |
1.3% |
| Lung Infection |
1.2% |
| Haematological Malignancy |
1.0% |
| Mucormycosis |
1.0% |
| Pneumonia Fungal |
1.0% |
| Sinusitis Fungal |
1.0% |
|
| Death |
11.8% |
| Drug Ineffective |
7.6% |
| Sepsis |
7.6% |
| Vomiting |
7.6% |
| Fusarium Infection |
4.9% |
| Liver Function Test Abnormal |
4.9% |
| Pancreatitis |
4.9% |
| Rash |
4.9% |
| Drug Interaction |
4.2% |
| Myalgia |
4.2% |
| Neutropenia |
4.2% |
| Pancytopenia |
4.2% |
| Respiratory Failure |
4.2% |
| Septic Shock |
4.2% |
| Thrombocytopenia |
4.2% |
| Aspergillosis |
3.5% |
| Congestive Cardiomyopathy |
3.5% |
| Paraesthesia |
3.5% |
| Polyneuropathy |
3.5% |
| Arrhythmia |
2.8% |
|
| Secondary |
| Product Used For Unknown Indication |
68.6% |
| Drug Use For Unknown Indication |
5.9% |
| Prophylaxis |
5.3% |
| Acute Myeloid Leukaemia |
4.8% |
| Aspergillosis |
2.1% |
| Hepatosplenic Candidiasis |
1.6% |
| Zygomycosis |
1.3% |
| Cytomegalovirus Infection |
1.2% |
| Graft Versus Host Disease |
1.2% |
| Fungal Infection |
1.1% |
| Gastrointestinal Candidiasis |
1.1% |
| Extravasation |
1.0% |
| Antifungal Prophylaxis |
0.7% |
| Atypical Mycobacterial Infection |
0.7% |
| Leukaemia |
0.7% |
| Gastrooesophageal Reflux Disease |
0.6% |
| Hypertension |
0.6% |
| Acute Leukaemia In Remission |
0.5% |
| Acute Promyelocytic Leukaemia |
0.5% |
| Aplasia |
0.5% |
|
| Toxic Epidermal Necrolysis |
17.8% |
| Sinoatrial Block |
8.2% |
| Renal Failure Acute |
6.8% |
| Cytolytic Hepatitis |
5.5% |
| Myositis |
5.5% |
| Overdose |
5.5% |
| Renal Disorder |
5.5% |
| Venous Stent Insertion |
5.5% |
| Bone Marrow Failure |
4.1% |
| Condition Aggravated |
4.1% |
| Drug Interaction |
4.1% |
| Pulmonary Oedema |
4.1% |
| Tinnitus |
4.1% |
| Arrhythmia |
2.7% |
| Aspergillosis |
2.7% |
| Epilepsy |
2.7% |
| General Physical Health Deterioration |
2.7% |
| Hyperbilirubinaemia |
2.7% |
| Jaundice |
2.7% |
| Necrotising Ulcerative Gingivostomatitis |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.2% |
| Drug Use For Unknown Indication |
13.7% |
| Prophylaxis |
11.3% |
| Acute Myeloid Leukaemia |
10.5% |
| Acute Lymphocytic Leukaemia |
5.3% |
| Nausea |
3.4% |
| Hypertension |
3.3% |
| Antifungal Prophylaxis |
2.9% |
| Chronic Graft Versus Host Disease |
2.8% |
| Pain |
2.7% |
| Prophylaxis Against Graft Versus Host Disease |
2.2% |
| Antiviral Prophylaxis |
1.7% |
| Bone Marrow Conditioning Regimen |
1.6% |
| Infection |
1.6% |
| Infection Prophylaxis |
1.6% |
| Diabetes Mellitus |
1.6% |
| Febrile Neutropenia |
1.5% |
| Constipation |
1.4% |
| Pneumonia |
1.4% |
| Anxiety |
1.3% |
|
| Sepsis |
10.7% |
| Death |
7.1% |
| Pyrexia |
7.1% |
| Toxic Encephalopathy |
7.1% |
| Staphylococcal Infection |
6.0% |
| Vomiting |
6.0% |
| Platelet Count Decreased |
4.8% |
| Pneumonia |
4.8% |
| Renal Failure Acute |
4.8% |
| Thrombocytopenia |
4.8% |
| Thrombotic Thrombocytopenic Purpura |
4.8% |
| Acute Pulmonary Oedema |
3.6% |
| Anaemia |
3.6% |
| Hypertension |
3.6% |
| Joint Swelling |
3.6% |
| Nausea |
3.6% |
| Nephrogenic Diabetes Insipidus |
3.6% |
| Neutropenic Colitis |
3.6% |
| Neutropenic Sepsis |
3.6% |
| Pharyngolaryngeal Pain |
3.6% |
|
| Interacting |
| Hepatosplenic Candidiasis |
14.6% |
| Zygomycosis |
14.0% |
| Product Used For Unknown Indication |
12.1% |
| Bone Marrow Failure |
10.8% |
| Convulsion Prophylaxis |
5.7% |
| Drug Use For Unknown Indication |
5.7% |
| Prophylaxis |
5.7% |
| Chronic Myeloid Leukaemia |
4.5% |
| Acute Myeloid Leukaemia |
3.8% |
| Acute Promyelocytic Leukaemia |
3.8% |
| Chronic Myeloid Leukaemia Transformation |
3.2% |
| Lung Transplant |
3.2% |
| Bronchopulmonary Aspergillosis |
2.5% |
| Transient Psychosis |
2.5% |
| Acute Leukaemia In Remission |
1.3% |
| Agitation |
1.3% |
| Antifungal Prophylaxis |
1.3% |
| Atrial Fibrillation |
1.3% |
| Breast Cancer |
1.3% |
| Hepatic Candidiasis |
1.3% |
|
| Drug Interaction |
25.7% |
| Vomiting |
11.4% |
| Sinoatrial Block |
7.1% |
| Tremor |
7.1% |
| Atrioventricular Block Second Degree |
5.7% |
| Malabsorption |
4.3% |
| Mesenteric Vein Thrombosis |
4.3% |
| Prescribed Overdose |
4.3% |
| Pulmonary Haemosiderosis |
4.3% |
| Sinus Tachycardia |
4.3% |
| Arrhythmia |
2.9% |
| Hypertriglyceridaemia |
2.9% |
| Metastases To Central Nervous System |
2.9% |
| Myocardial Infarction |
2.9% |
| Sinus Bradycardia |
2.9% |
| Bradycardia |
1.4% |
| Myositis |
1.4% |
| Pericardial Effusion |
1.4% |
| Psychotic Disorder |
1.4% |
| Pulmonary Haemorrhage |
1.4% |
|
